Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-12-05

FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Lannett Company, Inc)

View source ↗

Summary

FDA approved a supplemental application for levothyroxine sodium submitted by Lannett Company, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVOTHYROXINE SODIUM (levothyroxine sodium)

Snippet

SUPPL AP for LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)